STUDY OBJECTIVES: Metabolic syndrome (MetSyn) increases overall cardiovascular risk. MetSyn is also strongly associated with obstructive sleep apnea (OSA), and these 2 conditions share similar comorbidities. Whether OSA increases cardiovascular risk in patients with the MetSyn has not been investigated. We examined how the presence of OSA in patients with MetSyn affected hemodynamic and autonomic variables associated with poor cardiovascular outcome. DESIGN: Prospective clinical study. PARTICIPANTS: We studied 36 patients with MetSyn (ATP-III) divided into 2 groups matched for age and sex: (1) MetSyn+OSA (n = 18) and (2) MetSyn-OSA (n = 18). MEASUREMENTS: OSA was defined by an apnea-hypopnea index (AHI) > 15 events/hour by polysomnography. We recorded muscle sympathetic nerve activity (MSNA - microneurography), heart rate (HR), and blood pressure (BP - Finapres). Baroreflex sensitivity (BRS) was analyzed by spontaneous BP and HR fluctuations. RESULTS: MSNA (34 +/- 2 vs 28 +/- 1 bursts/min, P = 0.02) and mean BP (111 +/- 3 vs. 99 +/- 2 mm Hg, P = 0.003) were higher in patients with MetSyn+OSA versus patients with MetSyn-OSA. Patients with MetSyn+OSA had lower spontaneous BRS for increases (7.6 +/- 0.6 vs 12.2 +/- 1.2 msec/mm Hg, P = 0.003) and decreases (7.2 +/- 0.6 vs 11.9 +/- 1.6 msec/mm Hg, P = 0.01) in BP. MSNAwas correlated with AHI (r = 0.48; P = 0.009) and minimum nocturnal oxygen saturation (r = -0.38, P = 0.04). CONCLUSION: Patients with MetSyn and comorbid OSA have higher BP, higher sympathetic drive, and diminished BRS, compared with patients with MetSyn without OSA. These adverse cardiovascular and autonomic consequences of OSA may be associated with poorer outcomes in these patients. Moreover, increased BP and sympathetic drive in patients with MetSyn+OSA may be linked, in part, to impairment of baroreflex gain.
STUDY OBJECTIVES:Metabolic syndrome (MetSyn) increases overall cardiovascular risk. MetSyn is also strongly associated with obstructive sleep apnea (OSA), and these 2 conditions share similar comorbidities. Whether OSA increases cardiovascular risk in patients with the MetSyn has not been investigated. We examined how the presence of OSA in patients with MetSyn affected hemodynamic and autonomic variables associated with poor cardiovascular outcome. DESIGN: Prospective clinical study. PARTICIPANTS: We studied 36 patients with MetSyn (ATP-III) divided into 2 groups matched for age and sex: (1) MetSyn+OSA (n = 18) and (2) MetSyn-OSA (n = 18). MEASUREMENTS: OSA was defined by an apnea-hypopnea index (AHI) > 15 events/hour by polysomnography. We recorded muscle sympathetic nerve activity (MSNA - microneurography), heart rate (HR), and blood pressure (BP - Finapres). Baroreflex sensitivity (BRS) was analyzed by spontaneous BP and HR fluctuations. RESULTS: MSNA (34 +/- 2 vs 28 +/- 1 bursts/min, P = 0.02) and mean BP (111 +/- 3 vs. 99 +/- 2 mm Hg, P = 0.003) were higher in patients with MetSyn+OSA versus patients with MetSyn-OSA. Patients with MetSyn+OSA had lower spontaneous BRS for increases (7.6 +/- 0.6 vs 12.2 +/- 1.2 msec/mm Hg, P = 0.003) and decreases (7.2 +/- 0.6 vs 11.9 +/- 1.6 msec/mm Hg, P = 0.01) in BP. MSNAwas correlated with AHI (r = 0.48; P = 0.009) and minimum nocturnal oxygen saturation (r = -0.38, P = 0.04). CONCLUSION:Patients with MetSyn and comorbid OSA have higher BP, higher sympathetic drive, and diminished BRS, compared with patients with MetSyn without OSA. These adverse cardiovascular and autonomic consequences of OSA may be associated with poorer outcomes in these patients. Moreover, increased BP and sympathetic drive in patients with MetSyn+OSA may be linked, in part, to impairment of baroreflex gain.
Authors: Apoor S Gami; Brandi J Witt; Daniel E Howard; Patricia J Erwin; Lisa A Gami; Virend K Somers; Victor M Montori Journal: J Am Coll Cardiol Date: 2007-01-12 Impact factor: 24.094
Authors: Virend K Somers; David P White; Raouf Amin; William T Abraham; Fernando Costa; Antonio Culebras; Stephen Daniels; John S Floras; Carl E Hunt; Lyle J Olson; Thomas G Pickering; Richard Russell; Mary Woo; Terry Young Journal: Circulation Date: 2008-08-25 Impact factor: 29.690
Authors: J C B Ferreira; A V Bacurau; F S Evangelista; M A Coelho; E M Oliveira; D E Casarini; J E Krieger; P C Brum Journal: Am J Physiol Regul Integr Comp Physiol Date: 2007-10-31 Impact factor: 3.619
Authors: Fatima H Sert Kuniyoshi; Arturo Garcia-Touchard; Apoor S Gami; Abel Romero-Corral; Christelle van der Walt; Snigdha Pusalavidyasagar; Tomas Kara; Sean M Caples; Gregg S Pressman; Elisardo C Vasquez; Francisco Lopez-Jimenez; Virend K Somers Journal: J Am Coll Cardiol Date: 2008-07-29 Impact factor: 24.094
Authors: Felipe X Cepeda; Edgar Toschi-Dias; Cristiane Maki-Nunes; Maria Urbana P B Rondon; Maria Janieire N N Alves; Ana Maria F W Braga; Daniel G Martinez; Luciano F Drager; Geraldo Lorenzi-Filho; Carlos E Negrao; Ivani C Trombetta Journal: Sleep Date: 2015-07-01 Impact factor: 5.849
Authors: Edgar Toschi-Dias; Ivani C Trombetta; Valdo J D Silva; Cristiane Maki-Nunes; Felipe X Cepeda; Maria Janieire N N Alves; Glauce L Carvalho; Luciano F Drager; Geraldo Lorenzi-Filho; Carlos E Negrão; Maria Urbana P B Rondon Journal: Sleep Breath Date: 2018-06-11 Impact factor: 2.816
Authors: Ivani C Trombetta; Cristiane Maki-Nunes; Edgar Toschi-Dias; Maria-Janieire N N Alves; Maria Urbana P B Rondon; Felipe X Cepeda; Luciano F Drager; Ana Maria F W Braga; Geraldo Lorenzi-Filho; Carlos E Negrao Journal: Sleep Date: 2013-01-01 Impact factor: 5.849